Corsera Health is advancing a new approach to preventing cardiovascular disease, aiming to deliver an annual treatment that combines therapeutics with a disease risk tool called Klotho. The company was recently recognized by BioSpace as part of its NextGen Class of 2026, which highlights emerging biotech firms.
Chief Operating Officer Rena Denoncourt and Chief Financial Officer Meredith Kaya, both formerly with Alnylam Pharmaceuticals, discussed Corsera’s strategy in an interview with BioSpace. John Maraganore, former CEO of Alnylam, serves as Co-CEO and founder of Corsera. Clive Meanwell, also Co-CEO and managing partner at Population Health Partners, completes the leadership team.
Corsera is working on siRNA therapeutics developed in partnership with Axolabs in Germany. These therapies combine two novel siRNAs into a single product designed to prevent cardiovascular disease.
“It’s more about having a new way of looking at cardiovascular disease as something we can prevent, instead of something we need to wait and treat,” Denoncourt said. “That, I think, is what’s really going to change the overall trajectory of cardiovascular health at the population scale.”
The company’s lead candidate, COR-1004—an siRNA targeting PCSK9—is currently in Phase 1 trials. Another candidate, COR-2003, targets AGT and is expected to begin human testing later this year. Ultimately, Corsera plans to pair these approaches for an annual preventive treatment.
The shift toward addressing common diseases like heart disease comes amid broader industry trends favoring treatments for widespread conditions such as obesity—a movement supported by recent advances from companies like Novo Nordisk and Eli Lilly. Denoncourt noted that these developments have created favorable conditions for Corsera's efforts.
“We will not be constrained by the traditional ways of getting treatments to patients. We’ll be able to have a more nimble and disruptive way of getting the drug to large populations,” Denoncourt said.
Kaya pointed out that despite progress in cardiovascular medicine, many interventions arrive too late for patients. She emphasized Corsera's goal of intervening earlier in the disease process: “We have all the tools that we need to execute, but we have to do it now,” she said.
